Categories AlphaGraphs, Earnings, Technology
AVGO Earnings: Broadcom reports higher Q4 FY25 revenue, profit; results beat
Semiconductor company Broadcom, Inc. (NASDAQ: AVGO) on Thursday reported an increase in revenue and adjusted earnings for the fourth quarter of fiscal 2025. The numbers also surpassed analysts’ expectations.

Adjusted earnings rose sharply to $1.95 per share in the fourth quarter from $1.42 per share in the prior-year period, beating estimates. On an unadjusted basis, net income was $8.52 billion or $1.74 per share in Q4, vs. $4.32 billion or $0.90 per share in the fourth quarter of 2024.
Fourth-quarter revenues were $18.0 billion, compared to $14.1 billion in the corresponding quarter a year earlier. Revenues came in above analysts’ forecasts.
Broadcom’s CEO Hock Tan said, ” In Q4, record revenue of $18.0 billion grew 28% year-over-year, driven primarily by AI semiconductor revenue increasing 74% year-over-year. We see the momentum continuing in Q1 and expect AI semiconductor revenue to double year-over-year to $8.2 billion, driven by custom AI accelerators and Ethernet AI switches.”
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
After a rollercoaster year, is Tesla (TSLA) stock a good bet?
In recent years, Tesla's (NASDAQ: TSLA) stock has often swung between record highs and sharp corrections, reflecting shifts in investor sentiment, broader economic conditions, and changes in its financial performance.
Dollar Tree (DLTR), Dollar General (DG): Discount stores remain key gainers in a value-conscious landscape
Discount retailers Dollar Tree, Inc. (NASDAQ: DLTR) and Dollar General Corporation (NYSE: DG) have seen their stocks gain more than 30% in the past three months. The dollar stores continue
Everything you need to know about Aktis Oncology’s upcoming IPO
IPO activity in 2025 showed a marked rebound, led by the technology and healthcare sectors, after last year's sluggish performance. Aktis Oncology, which develops radiopharmaceuticals for solid tumors, is the